The Director General of Health Services (DGHC) under the Union Health Ministry on Wednesday issued guidelines for the management of COVID-19 in children below 18 years of age, according to which use of Remdesivir, an emergency use authorisation drug, has not been recommended and said that the usage of steroids in treating asymptomatic and mild cases of infection is harmful.
"Remdesivir, an emergency use authorisation drug, is not recommended in children. There is a lack of sufficient safety and efficacy data with respect to Remdesivir in children below 18 years of age," the guideline said.
"Steroids are not indicated and are harmful in asymptomatic and mild cases of COVID-19. It is indicated only in hospitalised moderately severe and critically ill COVID-19 cases under strict supervision. Steroids should be used at the right time, in the right dose, and for the right duration. Self-medication of steroids must be avoided," DGHC said in the guideline.
The guideline suggested only a rational usage of a high-resolution CT (HRCT) scan for knowing the extent and nature of lung involvement in COVID-19 positive patients.
"However, any additional information gained from HRCT scan of the chest often has little impact on treatment decisions, which are based almost entirely on clinical severity and physiological impairment. Therefore, treating physicians should be highly selective in ordering HRCT imaging of the chest in COVID-19 patients," it added.
The set of guidelines also suggested that children aged 5 years and under should not be required to wear masks.
"Children aged 5 years and under should not be required to wear masks. Children aged 6-11 years may wear a mask depending on the ability of the child to use a mask safely and appropriately under the direct supervision of parents/guardians. Children aged 12 years and over should wear a mask under the same conditions as adults," it said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)